OR WAIT 15 SECS
The BETR-D Study: The first and only randomized clinical trial on UVC Disinfection
Since its inception in 2007, UVC disinfection has been proven by multiple studies to be an effective means of enhanced terminal room disinfection to help stop the spread of HAIs such as C. diff, MRSA, VRE, Ebola and many more. This paper outlines the first and only randomized clinical trial on UVC disinfection, the Benefits of Enhanced Terminal Room-Disinfection (BETR-D) study, its results as well as subsequent studies that have resulted from the BETR-D study.
This Whitepaper, sponsored by Tru-D, will discuss:
Tru-D SmartUVC is the only smart UV disinfection device on the market. Powered by Sensor360™ technology and iTru-D, the company’s real-time data-tracking software application, Tru-D sets the gold standard of care for the health care disinfection market with innovative, high-efficiency capabilities. Tru-D is backed by proven data and clinical research accumulated over more than a decade by leading independent infection preventionists and epidemiologists across the U.S.
Data-driven and technology-inspired, Tru-D SmartUVC merges a 50-year history with the UV germicidal industry with the advancing possibilities of today’s technology to lead the health care industry in the eradication of harmful pathogens – today’s superbugs – making health care environments safer and improving quality of care for hospitals and health care facilities around the world.